The Role of Bone Resorption in the Etiopathogenesis of Acquired Middle Ear Cholesteatoma

Overview

Journal Eur Arch Otorhinolaryngol

Specialty Otorhinolaryngology

Date 2016 Dec 17

PMID 27981350

Citations 12

Authors

Shumin Xie

Xiaoli Wang

Jihao Ren

Wei Liu

Affiliations

Soon will be listed here.

Abstract

Cholesteatoma is a destructive squamous epithelial lesion of the temporal bone which gradually expands and leads to serious complications by destruction of nearby bony structures. Erosion caused by bone resorption of the ossicular chain and bony labyrinth may result in hearing loss, vestibular dysfunction, facial paralysis, labyrinthine fistulae and intracranial complications. The exact underlying cellular and molecular mechanism of bone resorption in acquired cholesteatoma still remains unexplained. Pubmed database and China National Knowledge Infrastructure were screened for articles focusing on bone resorption in acquired cholesteatoma. Osteoclast activation, pressure necrosis, acid lysis, enzyme mediation, inflammatory mediators and several newly discovered biomolecules are outlined as main theories behind bone resorption in acquired cholesteatoma, aiming to facilitate the development of potential therapeutic targets for preventing intracranial and extracranial complications caused by bone resorption in acquired middle ear cholesteatoma.

Citing Articles

PTHrP participates in the bone destruction of middle ear cholesteatoma via promoting macrophage differentiation into osteoclasts induced by RANKL.

Xie S, Jin L, Fu J, Yuan Q, Yin T, Ren J Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 49(5):655-666.

PMID: 39174879 PMC: 11341230. DOI: 10.11817/j.issn.1672-7347.2024.230482.

Hypoxia-inducible factor-1α contributes to the proliferation of cholesteatoma keratinocytes through regulating endothelin converting enzyme 1 expression.

Chen N, Xu L, Bi Z, Wu J Laryngoscope Investig Otolaryngol. 2024; 9(2):e1233.

PMID: 38525120 PMC: 10960243. DOI: 10.1002/lio2.1233.

The Relationship between the M1/M2 Macrophage Polarization and the Degree of Ossicular Erosion in Human Acquired Cholesteatoma: An Immunohistochemical Study.

Bassiouni M, Arens P, Zabaneh S, Olze H, Horst D, Rossner F J Clin Med. 2022; 11(16).

PMID: 36013064 PMC: 9410162. DOI: 10.3390/jcm11164826.

Microarray analysis and functional prediction of differentially expressed circular RNAs in acquired middle ear cholesteatoma.

Xie S, Jin L, Yin T, Ren J, Liu W Biomed Eng Online. 2021; 20(1):129.

PMID: 34922560 PMC: 8684697. DOI: 10.1186/s12938-021-00960-x.

The Effect of Zbxz23ir-21 NANO(nanomaterials) Delivery Vector on Apoptosis and PTEN(phosphatase and tensin homolog deleted on chromosome ten)/PI3K(Intracellular phosphatidylinositol kinase)/AKT(related to the A and C kinase) in Children with....

Zheng H, Wang W, Li S, Han L Bioengineered. 2021; 12(1):8809-8821.

PMID: 34696703 PMC: 8806951. DOI: 10.1080/21655979.2021.1984718.

References

Nabai L, Kilani R, Aminuddin F, Li Y, Ghahary A . Methotrexate modulates the expression of MMP-1 and type 1 collagen in dermal fibroblast. Mol Cell Biochem. 2015; 409(1-2):213-24. DOI: 10.1007/s11010-015-2526-8. View

Schonermark M, Issing P, Erbrich B, Lenarz T . Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma. Ann Otol Rhinol Laryngol. 1999; 108(3):245-52. DOI: 10.1177/000348949910800305. View

Kuczkowski J, Sakowicz-Burkiewicz M, Izycka-Swieszewska E, Mikaszewski B, Pawelczyk T . Expression of tumor necrosis factor-α, interleukin-1α, interleukin-6 and interleukin-10 in chronic otitis media with bone osteolysis. ORL J Otorhinolaryngol Relat Spec. 2011; 73(2):93-9. DOI: 10.1159/000323831. View

Foley J, Nickerson N, Riese 2nd D, Hollenhorst P, Lorch G, Foley A . At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. Odontology. 2012; 100(2):109-29. PMC: 3962551. DOI: 10.1007/s10266-012-0070-5. View

Si Y, Chen Y, Chen S, Zheng Y, Liu X, Liu Y . TLR4 drives the pathogenesis of acquired cholesteatoma by promoting local inflammation and bone destruction. Sci Rep. 2015; 5:16683. PMC: 4671024. DOI: 10.1038/srep16683. View

Zhu Z, Hong Y, Wang Y, He G, Ye S . [The significance of keratinocyte in hyperproliferation of middle ear cholesteatoma]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016; 30(2):139-43. View

Min K, Chae S, Kim D, DO S, Kim K, Lee H . Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer. Oncol Lett. 2015; 10(1):121-130. PMC: 4487011. DOI: 10.3892/ol.2015.3191. View

Kuczkowski J, Sakowicz-Burkiewicz M, Izycka-Swieszewska E . Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media. Am J Otolaryngol. 2009; 31(6):404-9. DOI: 10.1016/j.amjoto.2009.06.004. View

Juhasz A, Sziklai I, Rakosy Z, Ecsedi S, Adany R, Balazs M . Elevated level of tenascin and matrix metalloproteinase 9 correlates with the bone destruction capacity of cholesteatomas. Otol Neurotol. 2009; 30(4):559-65. DOI: 10.1097/MAO.0b013e31819fe6ed. View

10.

Fukudome S, Wang C, Hamajima Y, Ye S, Zheng Y, Narita N . Regulation of the angiogenesis of acquired middle ear cholesteatomas by inhibitor of DNA binding transcription factor. JAMA Otolaryngol Head Neck Surg. 2013; 139(3):273-8. DOI: 10.1001/jamaoto.2013.1750. View

11.

Abramson M, Moriyama H, Huang C . Pathogenic factors in bone resorption in cholesteatoma. Acta Otolaryngol. 1984; 97(5-6):437-42. DOI: 10.3109/00016488409132918. View

12.

Kobayashi T . MMP-2, -9 and TIMP-1, -2 assays in keratinocyte cultures. Methods Mol Biol. 2013; 1195:145-55. DOI: 10.1007/7651_2013_44. View

13.

Liu J, Lin G, Huang J, Jiang Z . [The expression of matrix metalloproteinase-1 and interleukin-1-alpha messenger ribonucleic acid in human middle ear cholesteatoma]. Zhonghua Er Bi Yan Hou Ke Za Zhi. 2003; 37(1):30-3. View

14.

Rezende C, Souto R, Rapoport P, Campos L, Generato M . Cholesteatoma gene expression of matrix metalloproteinases and their inhibitors by RT-PCR. Braz J Otorhinolaryngol. 2012; 78(3):116-21. PMC: 9446211. View

15.

Macri J, Chole R . Bone erosion in experimental cholesteatoma--the effects of implanted barriers. Otolaryngol Head Neck Surg. 1985; 93(1):3-17. DOI: 10.1177/019459988509300102. View

16.

Hirai H, Kariya S, Okano M, Fukushima K, Kataoka Y, Maeda Y . Expression of toll-like receptors in chronic otitis media and cholesteatoma. Int J Pediatr Otorhinolaryngol. 2013; 77(5):674-6. DOI: 10.1016/j.ijporl.2013.01.010. View

17.

Mehta D, Daudia A, Birchall J, Banerjee A . The localization of matrix metalloproteinases-8 and -13 in cholesteatoma, deep-meatal and post-auricular skin: a comparative analysis. Acta Otolaryngol. 2007; 127(2):138-42. DOI: 10.1080/00016480600781807. View

18.

Chen A, Wang B, Zhong F, Song G, Song H, Yu K . Expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin are associated with middle ear cholesteatoma risk. Acta Otolaryngol. 2015; 135(7):655-66. DOI: 10.3109/00016489.2015.1011789. View

19.

Suchozebrska-Jesionek D, Szymanski M, Kurzepa J, Golabek W, Stryjecka-Zimmer M . Gelatinolytic activity of matrix metalloproteinases 2 and 9 in middle ear cholesteatoma. J Otolaryngol Head Neck Surg. 2009; 37(5):628-32. View

20.

Wu M, Peng A, Sun M, Deng Q, Hazlett L, Yuan J . TREM-1 amplifies corneal inflammation after Pseudomonas aeruginosa infection by modulating Toll-like receptor signaling and Th1/Th2-type immune responses. Infect Immun. 2011; 79(7):2709-16. PMC: 3191966. DOI: 10.1128/IAI.00144-11. View